Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Evaluation of Investigational Contact Lenses

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02801396
Recruitment Status : Completed
First Posted : June 15, 2016
Results First Posted : June 9, 2017
Last Update Posted : July 11, 2017
Sponsor:
Information provided by (Responsible Party):
Johnson & Johnson Vision Care, Inc.

Brief Summary:
Single-visit, unmasked, non-dispensing study where subjects will wear three different lenses bilaterally in one visit, each lens being worn for approximately 30-60 minutes. Subjects will complete a questionnaire for each study lens.

Condition or disease Intervention/treatment Phase
Visual Acuity Device: Etafilcon A Design 1 (Test 1) Device: Etafilcon A Design 2 (Test 2) Device: Etafilcon A (Control) Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 116 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Actual Study Start Date : April 24, 2016
Actual Primary Completion Date : May 22, 2016
Actual Study Completion Date : May 22, 2016

Arm Intervention/treatment
Active Comparator: Group Sequence A, B, C
Subjects will wear Test 1, Test 2, and Control contact lenses in order according to the randomization sequence assigned for approximately 30-60 minutes each, with a 5-minute wash-out period between lenses.
Device: Etafilcon A Design 1 (Test 1)
Device: Etafilcon A Design 2 (Test 2)
Device: Etafilcon A (Control)
Active Comparator: Group Sequence B, C, A
Subjects will wear Test 1, Test 2, and Control contact lenses in order according to the randomization sequence assigned for approximately 30-60 minutes each, with a 5-minute wash-out period between lenses.
Device: Etafilcon A Design 1 (Test 1)
Device: Etafilcon A Design 2 (Test 2)
Device: Etafilcon A (Control)
Active Comparator: Group Sequence C, A, B
Subjects will wear Test 1, Test 2, and Control contact lenses in order according to the randomization sequence assigned for approximately 30-60 minutes each, with a 5-minute wash-out period between lenses.
Device: Etafilcon A Design 1 (Test 1)
Device: Etafilcon A Design 2 (Test 2)
Device: Etafilcon A (Control)
Active Comparator: Group Sequence C, B, A
Subjects will wear Test 1, Test 2, and Control contact lenses in order according to the randomization sequence assigned for approximately 30-60 minutes each, with a 5-minute wash-out period between lenses.
Device: Etafilcon A Design 1 (Test 1)
Device: Etafilcon A Design 2 (Test 2)
Device: Etafilcon A (Control)
Active Comparator: Group Sequence A, C, B
Subjects will wear Test 1, Test 2, and Control contact lenses in order according to the randomization sequence assigned for approximately 30-60 minutes each, with a 5-minute wash-out period between lenses.
Device: Etafilcon A Design 1 (Test 1)
Device: Etafilcon A Design 2 (Test 2)
Device: Etafilcon A (Control)
Active Comparator: Group Sequence B, A, C
Subjects will wear Test 1, Test 2, and Control contact lenses in order according to the randomization sequence assigned for approximately 30-60 minutes each, with a 5-minute wash-out period between lenses.
Device: Etafilcon A Design 1 (Test 1)
Device: Etafilcon A Design 2 (Test 2)
Device: Etafilcon A (Control)



Primary Outcome Measures :
  1. CLUE Handling [ Time Frame: 30 Minutes Post Insertion ]
    CLUE Handling is assessed using the Contact Lens User Experience (CLUE™) Questionnaire. CLUE™ is a validated patient-reported outcomes questionnaire to assess patient experience attributes of soft, disposable contact lenses (comfort, vision, handling, and packaging) in a contact lens-wearing population in the US, ages 18-65. Scores follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable / positive response. 97% of the scores fall within 0 and 120 (mean +/- 3XSD).

  2. Visual Performance (LogMar) [ Time Frame: 30 Minutes Post Insertion ]
    Distance time controlled Visual Performance (LogMAR) was assessed for each subject eye under bright-illumination high-contrast lighting conditions at 4m using an ETDRS chart. The average visual performance (LogMAR) was reported for each study lens.

  3. Percentage of Eyes With Acceptable Mechanical Lens Fit [ Time Frame: 30 Minutes Post Insertion ]
    Mechanical lens fit will be assessed for each subject and eye using a slit lamp. Lens fit is a binary response and 'Yes' = Acceptable Fit and 'No' = Unacceptable Fit. Lens fit is assessed using Lens centration, limbal exposure, primary gaze movement, up-gaze movement, edge lift, lens tightness. Unacceptable fit will be declared if there is any of the following present: limbal exposure, edge lift, excessive movement in primary or up-gaze or insufficient movement in primary gaze and up-gaze. The Percentage of subject eyes with acceptable lens fit will be reported.

  4. Percentage of Eyes With Acceptable Cosmetic Lens Fit [ Time Frame: 30 Minutes Post Insertion ]
    Cosmetic lens fitting is assessed for each subject eye in the primary gaze position without a slit lamp. Cosmetic lens fit is a binary response and is reported as acceptable or unacceptable. The Percentage of subject eyes with acceptable cosmetic lens fitting is reported.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Subjects must be at least 18 years of age and no more than 55 years of age (inclusive).
  2. The subject's vertex corrected best spherical distance refraction must be in the range of -1.00 to -6.00 Diopters (D) in each eye.
  3. The subject's vertex corrected cylindrical component of distance refraction must be less than or equal to -1.50 Diopters of Cylinder (DC) in each eye.
  4. Subjects must have best corrected visual acuity of 20/25 (Snellen or equivalent) or better in each eye.
  5. Subjects must self-report as being Asian race.
  6. Subjects must self-report as having brown or black eyes.
  7. Subjects must be habitual lens wearer (clear or limbal ring cosmetic) . Habitual is defined as at least one (1) month of Contact Lens wear where the lenses were worn for a minimum of six (6) hours per day and a minimum of three (3) days per week.
  8. Subjects between 18 to 39 years old must be habitual limbal ring cosmetic lens wearers or must have tried limbal ring cosmetic lens within the past two years.
  9. Subjects must be cosmetic contact lens concept acceptors as determined by screening questionnaire.
  10. Subjects must possess a functional / usable pair of spectacles and bring them to the visit (only if applicable - to the investigator's discretion).
  11. Subjects must read, understand, and sign the Statement of Informed Consent.
  12. Subjects must appear able and willing to adhere to the instructions set forth in the clinical protocol.
  13. Subjects must be willing to have their eyes video recorded and photographed.

Exclusion Criteria:

  1. Working for any advertising agency, any company involved in public relations or marketing, market research; or any company that makes or sells contact lenses or glasses.
  2. Participated in any paid market research within the past 3 months.
  3. Pregnant or breast feeding a baby.
  4. Subjects with diabetes.
  5. Any ocular or systemic allergies or disease which might interfere with contact lens wear.
  6. Any systemic disease, or autoimmune disease, which might interfere with contact lens wear, at investigator's discretion.
  7. Using medications during and immediately preceding the study period that may interfere with current contact lens wear as determined by the investigators
  8. Any infectious diseases (e.g. hepatitis, tuberculosis) or a contagious immunosuppressive disease (e.g. HIV), by self-report.
  9. Any grade 3 or greater Biomicroscopy findings (this includes, corneal edema, corneal staining, corneal vascularization, conjunctival injection, tarsal abnormalities, bulbar injection) on the FDA classification scale.
  10. Any active ocular abnormalities/conditions that might interfere with contact lens wear (this includes, but not limited to, chalazia, recurrent styles, pterygium, infection etc.).
  11. Any corneal distortion, scar, or opacity affecting vision as noted by subjects or investigators during examination.
  12. History of any corneal surgery (e.g. radial keratotomy (RK), photorefractive keratectomy (PRK), laser-assisted in situ keratomileusis (LASIK)); confirmed with topography if necessary at the investigator's discretion.
  13. Habitual wearers of rigid gas permeable or orthokeratology lens within the past 3 months.
  14. Current habitual contact lens modality for extended wear or conventional wear (contact lenses with a replacement schedule of 3 months to >1 year).
  15. Participation in any pharmaceutical, medical device, or contact lens related clinical research trial within 14 days prior to study enrollment. This excludes studies that do not require product treatment/intervention.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02801396


Locations
Layout table for location information
Hong Kong
Hong Kong Polytechnic University
Hong Hom, Kowloon, Hong Kong
Sponsors and Collaborators
Johnson & Johnson Vision Care, Inc.
Layout table for additonal information
Responsible Party: Johnson & Johnson Vision Care, Inc.
ClinicalTrials.gov Identifier: NCT02801396    
Other Study ID Numbers: CR-5759
First Posted: June 15, 2016    Key Record Dates
Results First Posted: June 9, 2017
Last Update Posted: July 11, 2017
Last Verified: June 2017

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Product Manufactured in and Exported from the U.S.: Yes